Quick Answer
Summit Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2024.
Summit Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $0.00 | $0.00 -100.0% |
$705.0K -61.0% |
$1.81M +110.3% |
$860.0K -98.5% |
| Revenue (ASC 606) | — | $0.00 | $0.00 -100.0% |
$705.0K -61.0% |
$1.81M +110.3% |
$860.0K -98.5% |
| Net Income | -$1.08B -387.8% |
-$221.31M +64.0% |
-$614.93M -680.5% |
-$78.78M +11.1% |
-$88.60M -68.1% |
-$52.70M -584.8% |
| Diluted EPS | -$1.44 -364.5% |
-$0.31 +68.7% |
-$0.99 -141.5% |
-$0.41 +38.8% |
-$0.67 +11.8% |
-$0.76 -220.6% |
| Total Assets | $751.18M +72.5% |
$435.56M +114.6% |
$202.95M -69.4% |
$664.17M +485.8% |
$113.37M +10.6% |
$102.50M +69.0% |
| Cash and Equivalents | $225.27M +114.8% |
$104.86M +46.8% |
$71.42M -79.5% |
$348.61M +385.6% |
$71.79M +8.1% |
$66.42M +4.0% |
| Stockholders Equity | $658.86M +69.5% |
$388.75M +400.4% |
$77.69M -38.7% |
$126.65M +52.1% |
$83.28M +4.8% |
$79.45M +38.0% |
| R&D Expense | — | — | $59.47M +14.4% |
$52.00M -39.1% |
$85.35M +60.2% |
$53.27M +2.4% |
| Operating Income | — | -$226.00M +62.9% |
-$609.65M -745.7% |
-$72.09M +16.4% |
-$86.19M -62.0% |
-$53.19M -1087.1% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 775.37M +5.1% |
737.63M +5.1% |
701.66M +232.4% |
211.09M +115.3% |
98.04M +45.8% |
67.23M +0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$231.79M | -312.0% | +59.0% |
| Diluted EPS | September 30, 2025 | -$0.31 | -287.5% | +59.2% |
| Total Assets | September 30, 2025 | $261.73M | -48.0% | -19.2% |
| Cash and Equivalents | September 30, 2025 | $238.55M | +154.4% | -19.9% |
| Stockholders Equity | September 30, 2025 | $192.26M | -56.1% | -25.9% |
| R&D Expense | March 31, 2024 | $30.87M | +212.4% | +101.5% |
| Operating Income | September 30, 2024 | -$58.38M | -184.9% | +2.1% |
| Shares Outstanding | September 30, 2025 | 744.44M | +1.0% | +0.2% |
- Summit Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2024.
- Summit Therapeutics Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2024.
- Summit Therapeutics Inc. reported Net Income of -$1.08 billion for fiscal year 2025.
- Summit Therapeutics Inc. showed a decrease of -387.8% in Net Income compared to the prior fiscal year.
- Summit Therapeutics Inc. reported Diluted EPS of $1.44 per share (loss) for fiscal year 2025.
- Summit Therapeutics Inc. showed a decrease of -364.5% in Diluted EPS compared to the prior fiscal year.
- Summit Therapeutics Inc. reported Total Assets of $751.18 million for fiscal year 2025.
- Summit Therapeutics Inc. showed an increase of +72.5% in Total Assets compared to the prior fiscal year.
- Summit Therapeutics Inc. reported Cash and Equivalents of $225.27 million for fiscal year 2025.
- Summit Therapeutics Inc. showed an increase of +114.8% in Cash and Equivalents compared to the prior fiscal year.
- Summit Therapeutics Inc. reported Stockholders Equity of $658.86 million for fiscal year 2025.
- Summit Therapeutics Inc. showed an increase of +69.5% in Stockholders Equity compared to the prior fiscal year.
- Summit Therapeutics Inc. reported R&D Expense of $59.47 million for fiscal year 2023.
- Summit Therapeutics Inc. showed an increase of +14.4% in R&D Expense compared to the prior fiscal year.
- Summit Therapeutics Inc. reported Operating Income of -$226.00 million for fiscal year 2024.
- Summit Therapeutics Inc. showed an increase of +62.9% in Operating Income compared to the prior fiscal year.
- Summit Therapeutics Inc. reported Gross Profit of -$25.33 million for fiscal year 2019.
- Summit Therapeutics Inc. showed a decrease of -1047.7% in Gross Profit compared to the prior fiscal year.
- Summit Therapeutics Inc. reported Shares Outstanding of 775.37 million shares for fiscal year 2025.
- Summit Therapeutics Inc. showed an increase of +5.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: